iShares Biotechnology ETF (IBB), issued by BlackRock, reported 250 long positions and $9.1B in net assets in its Jun 2026 N-PORT filing. The ten largest positions account for 54.33% of net assets.
Reporting period: 30 Jun 2026 · 9 filings on file · N-PORT is filed monthly and published quarterly, roughly 60 days in arrears
Net assets
$9.1B
As of Jun 2026
Positions
250
Long positions in the filing
Top 10 weight
54.33%
Top 25: 75.43%
Effective holdings
23
Concentrated
Cash
0.00%
Share of net assets
Securities on loan
11.6324%
183 positions on loan
Sector exposure
5 sectors · Jun 2026
Health Care75.76%
Funds10.76%
Unclassified10.34%
Technology3.13%
Materials0.01%
Ten largest holdings
Top 10 of 252 positions · Jun 2026
Ten largest holdings reported by IBB as of 30 Jun 2026
#
Security
CUSIP
Value
% of net assets
1
BCF INSTITUTIONAL-SL AGNCY
066922519
$1.1B
11.66%
2
VERTEX PHARMACEUTICALS INC
92532F100
$734.3M
8.08%
3
AMGEN INC
031162100
$711.4M
7.83%
4
GILEAD SCIENCES INC
375558103
$621.8M
6.84%
5
REGENERON PHARMACEUTICALS
75886F107
$445.9M
4.91%
6
ARGENX SE - ADR
04016X101
$341.6M
3.76%
7
ALNYLAM PHARMACEUTICALS INC
02043Q107
$283.6M
3.12%
8
NATERA INC
632307104
$262.7M
2.89%
9
REVOLUTION MEDICINES INC
76155X100
$252.7M
2.78%
10
BIOGEN INC
09062X103
$224.1M
2.47%
Full holdings, position changes between periods, fund overlap, cross-fund crowding and securities lending detail for IBB are in the ETF X-Ray dashboard.